RECRUITING

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

Talk to us

Conditions

Foot Injuries and DisordersAnkle Injuries and DisordersAchilles Tendon InjuryVAS scale: visual analog scaleMedrol Dosepak

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries. The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

Official Title

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

Quick Facts

Study Start:2025-01
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06780202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 95 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * Concurrent or significant injuries to other bones or organs
  2. * Local infections
  3. * History of alcohol or medical abuse, including prior opioid abuse
  4. * Smoking
  5. * History of severe heart disease, renal failure, liver dysfunction, active peptic ulcer disease, diabetes, rheumatoid arthritis, neurological or psychiatric diseases that could influence pain perception
  6. * Pre-existing immune suppression
  7. * Those deemed possibly non-compliant by the study team and,
  8. * All vulnerable populations (those unable to give consent, juveniles, pregnant women, prisoners, cognitively impaired and non-English speaking).

Contacts and Locations

Study Contact

Jason Bariteau, MD
CONTACT
404-778-3350
jason.bariteau@emory.edu

Principal Investigator

Rishin Kadakia, MD
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

Emory Musculoskeletal Institute, Emory Orthopaedics & Spine Center
Atlanta, Georgia, 30329
United States
Emory Sports Medicine Complex and Emory Orthopaedics and Spine Center
Johns Creek, Georgia, 30022
United States

Collaborators and Investigators

Sponsor: Emory University

  • Rishin Kadakia, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01
Study Completion Date2026-12

Study Record Updates

Study Start Date2025-01
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • VAS scale: visual analog scale
  • Medrol Dosepak

Additional Relevant MeSH Terms

  • Foot Injuries and Disorders
  • Ankle Injuries and Disorders
  • Achilles Tendon Injury